In fight for GSK's Advair, generic firms step carefully on price

LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.

Source: Reuters: Health - June 3, 2016 Category: Consumer Health News Tags: healthNews Source Type: news